Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185773 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL16900674 | 0.81 | TRPA1 (0.46) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL18988641 | 0.78 | TRPA1 (0.46) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL7118507 | 0.77 | MAPT (0.52) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL7118504 | 0.77 | MAPT (0.52) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL7127867 | 0.76 | CA1 (0.50) | TRPA1HTR7PKMKMT2AHTR1A | |
| SCHEMBL7127875 | 0.76 | CA1 (0.50) | TRPA1HTR7PKMKMT2AHTR1A | |
| SCHEMBL7116937 | 0.75 | CYP3A4 (0.51) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL7116934 | 0.75 | CYP3A4 (0.51) | CYP3A4CYP2C19TRPA1MAPTHTR7 | |
| SCHEMBL12416941 | 0.74 | HTR7 (0.41) | CYP3A4CYP2C19TRPA1MAPTHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344497-B1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2014-03-05 | — | — | EP | disclosed |
| US-8637541-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8637541-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8637541-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-21 | — | — | US | disclosed |
| EP-2342201-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Canada Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010031182-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031182-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | CYP3A4 2886/4885CYP2C19 1292/4885TRPA1 1350/4885 |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, MTNR1B, MTNR1A | CYP3A4 1821/4885CYP2C19 849/4885TRPA1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.